Project Grant R43AG087766
Award Date
6/15/25
Completion Date
8/31/26
Dollars Obligated
$392K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $504,505 in funding to Bolden Therapeutics Inc. to conduct preclinical characterization of splice-modifying antisense oligonucleotides (ASOs) targeting neurogenesis in human Alzheimer's disease (AD) neural cells. The goal of this Phase I effort is to evaluate lead candidate exon-skipping ASOs in human neural cell culture, with the aim of modulating target expression, altering protein...
This $679,424 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports preclinical studies to evaluate the efficacy of a novel nanoligomer treatment for reducing neuroinflammation and protecting against cognitive decline in mouse models of brain aging and Alzheimer's disease. The research aims to determine the ideal application of the NF-kB/NLRP3-targeted nanoligomer treatment, whether for prevention during aging or treatment of pathology, and to...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This $3,357,206 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) supports the clinical evaluation of a novel compound, BMS-984923, for the treatment of Alzheimer's disease (AD). The grant recipient, Allyx Therapeutics Inc., has an exclusive license for the use of BMS-984923 in neurodegenerative diseases from Bristol Myers Squibb and Yale University. Preliminary studies have demonstrated the compound's efficacy in improving synapse density, hippocampal...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research program) provides $1,649,586 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research on discovering and optimizing "APOE4 correctors" for the treatment of Alzheimer's disease. The key products and services to be delivered include: Developing and miniaturizing a high-throughput cellular thermal shift assay (BITSA) to rapidly screen for small molecules that can stabilize the...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $751,442 provides funding to the University of California, Los Angeles (UCLA) to develop and evaluate a CRISPR-based gene editing therapy for Alzheimer's disease (AD). The key objectives are to: Optimize the delivery of CRISPR components, using synthetic exosome (SE) nanoparticles, to efficiently edit the APOE4 gene to the less pathogenic APOE3 variant in the brain of AD model mice....
This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will support Sxrna Technologies, Inc. in developing an organoid toolkit for Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). The company aims to create a platform for identifying senescent cells in living tissue, which can provide insights into the aging process and enable high-throughput drug screening in complex 3D tissue models. Specifically, the grant will fund...
The National Institute on Aging (CFDA 93.866) awarded a $1,274,993 Project Grant to Epicypher, Inc. to develop a new approach called Reverse Transcribe & Tagmentation (RT & TAG) for identifying chromatin-associated RNAs (CARNAs), including nascent RNA transcripts, to accelerate aging and Alzheimer's disease/age-related dementia (AD/ADRD) research. The central innovation is an immunotethering-based method for in situ targeted tagmentation of CARNAs. The project also involves developing...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...